Kaki Diabetik (KD) 
Diabetes mellitus (DM) is known as an emerging chronic disease world wide. DM is accepted as cardiovascular risk factor and therefore plays an important role in the pathogenesis of cardiovascular disease. Peripheral artery disease (PAD) is one of the major health problems resulting from macrovascular complication in diabetic patients. As a manifestation of atherosclerosis, PAD is characterized by atherosclerotic occlusive disease of the lower extremities and is a marker for atherothrombotic disease in other vascular beds. PAD is present in approximately one-half of all patients with foot ulcers. [1] [2] [3] [4] Along with polyneuropathy, PAD causes foot ulceration which often leads to lower limb amputations.
DM causes almost 50% of all non traumatic lowerextremity amputations world wide. It is estimated that the life time risk for amputation in diabetic patients is 10-15%, which is 10-30 times higher in comparison to the general population. [5] [6] [7] [8] In Germany the number of limb amputation is increasing. According to the newest data from German Association of Angiology, which were released during the Scientifi c Meeting in Mannheim in September 2008, about 60.000 amputations are performed every year. Compared to european countries such as Denmark and The Netherlands, Germany is leader in the number of limb amputation. The main factors inducing these amputations are diabetic foot (DF) or arteriosclerosis. Almost every 3 rd patient suffers from diabetes mellitus. An amputation for elderly patients resembles a fatal step in their quality of life.
In the other hand, the patients are often late to seek specialized professional care or they are not treated in a vascular center. These factors along with pathology-anatomical factors limit the possibilities for revascularisation.
The strengths and limitations of surgical revascularisation in PAD are well known. Surgical revascularisation and percutaneous interventions are limited to patients with critical limb ischemia (CLI) and those with disabling claudication (Fontaine Stadium IIb-IV) due to discrete proximal disease.
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Endothelial functions and dysfunctions
As key elements in the maintenance of tissue homeostasis, blood vessels serve as the conduits of circulation, transporting nutrients and oxygen to organs and tissues, and removing destructive catabolites and xenobiotics from the blood fl ow.
For a long time two specialized endothelial functions were accepted: gas exchange in pulmonary circulation and fenestration in hepatic and splenic circulation. Under normal homeostatic conditions, the endothelium resists vasospasm, prevents leukocyte and platelet adhesion to the vessel wall, favours fi brinolysis, combats coagulation of blood, and inhibits the proliferation of vasculars mooth muscle cells.
During the last two decades, accumulating evidence has described the vascular endothelium as an active endocrine, paracrine, and autocrine organ, indispensable for the maintenance of vascular homeostasis. Altered homeostasis induced by various stimuli may cause localized alterations, or 'endothelial dysfunction', of the antihemostatic properties, vascular tone, heightened leukocyte adhesion, and increased production of cytokines and growth factors. The dramatic change of endothelial interactions with blood leukocyte soccurring in infl ammation provides an example of endothelial activation. 10, 12, 13 Diabetes mellitus and endothelial dysfunction Vascular diseases, including atherosclerosis, medial calcifi cation, and microangiopathy, are prevalent in patients with DM and are the principal causes of morbidity and mortality in these individuals. Atherosclerosis occurs earlier in patients with diabetes, frequently with greater severity and more diffuse distribution.
Hyperglycemia per se causes endothelial dysfunction. Healthy humans exposed to a hyperglycaemic clamp suffi cient to increase forearm glucose concentration experience impaired endothelium-dependent vasodilation. 10, 14, 15 Hyperglycemia also decreases fl owmediated endothelium-dependent vasodilation of the brachial artery of healthy subjects. 14, 16, 17 Hyperglycemia may decrease the bioavailability of nitric oxide (NO) through multiple mechanisms (Figure1). Additionally, hyperglycemia may increase the formation of oxygen-derived free radicals that inactivate NO or cause intracellular signalling disturbances that inhibit nitric oxide synthase (NOS) activity and thereby reduce NO production. Hyperglycemia is also associated with increased oxidative stress. Increased inactivation of NO by oxygen-derived free radicals and decreased production of NO by NOS reduce NO levels in the vascular milieu. 14, [17] [18] [19] [20] Rationale for stem cell therapy in diabetic foot
The essential part of normal wound healing is the formation of new blood vessels with in the provisional wound matrix that is referred to as granulation tissue. Neovascularisation of the granulation tissue occurs by the processes of angiogenesis or vasculogenesis, or both. 21, 22 Therapeutic angiogenesis has been studied many times for the treatment of patients with peripheral arterial occlusive disease who do not qualify for surgical revascularisation or radiologic intervention. Angiogenesis can be achieved by introducing growth factors as mature proteins or as complementary DNA carrying vector systems (cDNA-plasmid) or stem cells which contain endothelial progenitor cells (EPCs) and mesenchymal cells. [23] [24] [25] [26] [27] The following sections discuss various methods of using stem cell therapies to induce angiogenesis in DF.
Defi nition of stem cells
All life forms begin with a stem cell, which is defi ned as a cell that has the dual ability to self-renew and to produce progenitors and different types of specialized cells in the organism. 28 Regardless of their sources, stem cells are defi ned by their indefi nite capability of self-renewal (proliferation) and unlimited potential to generate specialized tissue cells (differentiation) (Figure2). Currently, scientists and clinical researchers are working on two major types of stem cells, embryonic and adult, which share three characteristic properties: 1. Stem cells are premature, undifferentiated, or unspecialized. However, unspecialized stem cells can generate specialized cells, including heart muscle, blood vessels, blood cells, or nerve cells. 2. Stem cells can divide and renew themselves for long periods. Unlike other cells-which normally do not replicate by themselves-stem cells may replicate, or proliferate, many times. 3. Stem cells can respond to exogenous or endogenous signals by generating specialized cell types. When unspecialized stem cells develop into specialized cell, the process is called differentiation. 29 
Figure 1. Sources for embryonic and adult stem cells 28
Adult and embryonic stem cells
Human embryonic stem cells (ESCs) used for research have been extracted from embryos created by in vitro fertilization done by the group of James Thomson in 1998 and they reported on the etablishment of human ESC lines. They concluded that the ESCs have potential to form most cell types of the adult body over almost unlimited periods. 28, [30] [31] [32] The adult body has a small number of adult or somatic stem cells in some tissues and organs. Such adult stem cells (ASCs) have been known to posses the ability to regenerate the corresponding tissue from which they are derived. Hematopoietic stem cells (HSCs), for example, continuously regenerate the circulating blood cells and cells of the immune system during the life span of the organism. Based on animal studies, many researchers have recently claimed that ASCs might exhibit developmental potentials comparable to those exhibited by ESCs. ASCs have the ability to regenerate the tissue from which they are derived over the life span of the individual, while ESCs have the potential to form most cell types of the adult body over very long periods of in vitro cultivation. 28, 29, [32] [33] [34] [35] [36] [37] [38] However, until now the use of human ESCs for research is prohibited in Germany. Many clinical research centers in Germany are focusing to develop the potential of ASCs.
Endothelial progenitor cells for cardiovascular regeneration
The differentiation of mesodermal cells to angioblasts and subsequent endothelial differentiation was believed to occur exclusively in embryonic development. Asahara et al. reported that purifi ed CD34+ hematopoietic progenitor cells from adults can differentiate ex vivo to an endothelial phenotype. 40, 41 These cells were named "endothelial progenitor cells" (EPC). Shi et al. reported in 1998 the existence of 'circulating bone marrowderived endothelial progenitor cells' (CEPC). 58 This is actually a similar fi nding to Asahara. EPC or CEPC were defi ned as cells, which express both, hematopoietic stem cell markers such as CD34 and an endothelial marker protein such as the VEGF-receptor KDR.
CD34 is not expressed exclusively on hematopoietic stem cells (HSC) but also on mature endothelial cells. Further studies used the more immature HSC marker CD133 also known as prominin or AC 133. Purifi ed isolated CD 133 + cells also differentiated to endothelial cells in vitro. 41, 42 However, the biological function of CD133 remains unclear. It is not well known whether CD133 only represents a surface marker or has a functional activity involved in regulation of neovascularisation. 41 The characterization of EPC becomes particularly difficult when cells are expanded and cultured ex vivo, since the culture conditions (culture supplements such as fetal calf serum and cytokines or different plastic types) rapidly change the phenotype of the cells. Moreover, continuous cultivation was shown to increase endothelial differentiation, as evidenced by elevated endothelial marker protein expression.
Smooth muscle cells (SMC) and endothelium are two essential structures for the architecture of the blood vessels. Vascular stem cells, a group of multipotent heterogenous stem cells, largely fall into two subgroups: endothelial and SMC progenitors. EPC develop closely from CD34 + to bone marrow stem cells, in particular those committed to the monomyeloid cell lineage, whereas SMC progenitors may belong or originate together in mesenchymal stem cells (MSC), which are negative for CD34. Atherosclerosis causes arterial wall damage and impairs the capacity of both vascular stem cell types to regenerate neovascular tissue, or may trigger abnormal proliferation or death by apoptosis under different pathological conditions. 29 
Mechanism of vessel formation
Angiogenesis is defi ned as the sprouting of new capillaries from existing vascular structure, a process that is triggered by endothelial cell migration and proliferation. Remodelling of the extra cellular matrix (ECM), tubule formation and expansion of the surrounding vascular tissue are key elements of angiogenesis.
The in situ formation of new blood vessels from ECP which differentiated into endothelial cells and fuse into luminal structures is called vasculogenesis.
Meanwhile, arteriogenesis refers to an increase in the calibre of pre-existing arteriolar collateral connections by recruitment of perivascular cells and expansion and remodelling of the extracellular matrix. Arteriogenesis increases the size and wall thickness of collateral vessels, and shear stress (rather than hypoxia) seems to be the main factor that stimulates arteriogenesis. 9 The key steps in vessel formation-namely endothelial cell activation, migration, proliferation and reorganisation-are tightly regulated in a complex balance between pro-and anti-angiogenic mechanisms (Table1). The most important pro-angiogenic factors are vascular endothelial growth factor (VEGF) and basic fi broblast growth factor (bFGF), also known as FGF-2. VEGF is an endothelial cell specifi c mitogen that is markedly upregulated by hypoxia, and plays an important role in endothelial cell proliferation, differentiation and survival.
FGFs are non-secreted growth factors that are released only during cell death or ischemic cell injury. Clinical and biochemical factors also infl uence the formation of, and biological response to different angiogenic growth factors. Hypoxia, for example, is the most potent inducer of angiogenesis, 44 principally via up-regulation of VEGF, whereas diabetes mellitus and increased levels of cholesterol and lipoprotein(a) are associated with a reduced angiogenic response. 9 As bone marrow-derived stem and progenitor cells home to sites of ischemia, this may allow the local release of factors acting in paracrine manner on the surrounding ischemic tissue. Bone marrow-derived mononuclear cells release angiogenic growth factors such as VEGF, bFGF and angiopoietins, thereby enhancing the local angiogenic response. 9, 41, 44 This mechanism is named 'homing' and it is the most likely theory which represents the reality in ischemic process.
During tissue injury, e.g. wound, the formation of new blood vessels is needed. Neovascularization of the wound's granulation tissue occurs by the processes mentioned above. However, in diabetic patients these angiogenic mechanisms are reduced.
The idea to induce neovascularisation in the wound area or ischemic area is now a hot topic in regenerative medicine. There are a lot of clinical trials in this area, however only few centers world wide perform these studies.
Stem cell transplantation
Until now, there are a lot of protocols, hypotheses, debates and discussions about the best methods of stem cell transplantation. Most clinical studies are performing 2 methods of stem cell transplantation: intra-arterial and intra-muscular.
The concept of intra-arterial stem cell transplantation assures that the stem cells reach all stenosis sites antegradely. We believe that the stenosis area is the ischemic area which stimulates the homing effect of the cells.The intra-muscular application is based on the ischemic musculature which could be supplied with a high concentration of stem cells through several local depots. Whether the cells reached the ischemic area by blood fl ow remains unclear. In theory, it induces the homing effect and then stimulates the angiogenesis or vasculogenesis in the ischemic area.
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Current clinical trial
There are a lot of clinical trials running on this topic ( Table 2 ). However, the outcomes have not been published yet. Only some studies published their results or case reports. 25, 45, 46 A multi center study has not been performed to take conclusion of stem cell therapy. To what we know, the data from other centers as well as ours show positive results (Figure 3 ). In conclusion, bone marrow derived EPCs are the newest cellular target that may be used to infl uence postnatal neovascularisation. The formation of new blood vessels, including collaterals, is a complex physiological process that occurs in adults in response to tissue injury or ischemia.
The stem cell transplantation to induce vessel formation is promising and could be a new therapeutic option in the future to treat limb ischemia without options of revascularization. However, there is still much to learn about the optimum treatment modality, dosing frequency and route of administration, especially in patients with diabetes mellitus. We know that these patients have a reduced capability of vascular self-renewing.
Until now, there are only some reports and clinical trials which have already been fi nished with the whole evaluations and they show an improvement of blood perfusion in ischemic area. Moreover, multicenter studies with large numbers of patients are expected to give more information about stem cell therapy.
